Loading...
XSHE300676
Market cap2.22bUSD
Jan 16, Last price  
39.54CNY
1D
-0.73%
1Q
-14.27%
IPO
83.06%
Name

BGI Genomics Co Ltd

Chart & Performance

D1W1MN
XSHE:300676 chart
P/E
175.51
P/S
3.75
EPS
0.23
Div Yield, %
0.00%
Shrs. gr., 5y
0.61%
Rev. gr., 5y
11.39%
Revenues
4.35b
-38.27%
794,839,3481,047,380,6461,131,981,8471,318,703,6231,711,498,2532,095,544,2712,536,406,1052,800,411,9368,397,230,0026,766,137,3157,046,132,0814,349,637,250
Net income
93m
-88.43%
81,734,191135,880,89728,120,733262,099,904332,690,944398,091,510386,645,517276,334,0182,090,285,2731,461,536,272802,765,40892,900,396
CFO
409m
+199.73%
72,488,80036,701,6000328,682,815234,073,624226,570,84714,687,326224,254,9613,602,692,5312,476,132,383136,378,792408,767,851
Dividend
Jul 04, 20240.1 CNY/sh
Earnings
May 09, 2025

Profile

BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.
URL
https://www.bgi.com/
IPO date
Jul 14, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,349,637
-38.27%
7,046,132
4.14%
Cost of revenue
3,386,221
5,642,406
Unusual Expense (Income)
NOPBT
963,416
1,403,726
NOPBT Margin
22.15%
19.92%
Operating Taxes
21,854
197,515
Tax Rate
2.27%
14.07%
NOPAT
941,562
1,206,211
Net income
92,900
-88.43%
802,765
-45.07%
Dividends
(143,470)
Dividend yield
0.68%
Proceeds from repurchase of equity
82,851
(299,268)
BB yield
-0.42%
1.41%
Debt
Debt current
24,184
809,536
Long-term debt
351,176
273,360
Deferred revenue
19,675
Other long-term liabilities
15,393
1
Net debt
(5,609,274)
(5,403,210)
Cash flow
Cash from operating activities
408,768
136,379
CAPEX
Cash from investing activities
(1,750,741)
Cash from financing activities
(266,882)
FCF
183,137
173,909
Balance
Cash
5,485,951
6,389,691
Long term investments
498,682
96,416
Excess cash
5,767,152
6,133,800
Stockholders' equity
5,176,682
5,978,621
Invested Capital
5,150,343
5,085,663
ROIC
18.40%
22.60%
ROCE
9.32%
12.63%
EV
Common stock shares outstanding
412,341
409,914
Price
48.00
-7.14%
51.69
-41.13%
Market cap
19,792,361
-6.59%
21,188,464
-41.38%
EV
14,327,870
15,930,343
EBITDA
1,400,252
1,856,761
EV/EBITDA
10.23
8.58
Interest
91,560
100,764
Interest/NOPBT
9.50%
7.18%